Theravance Biopharma, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $107.5M | $64.4M | $57.4M | $51.3M | $55.3M | $71.9M | $73.4M | $60.4M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $37.4M | $37.6M | $40.6M | $63.4M | $193.7M | $261.0M | $219.2M | $201.3M |
| SG&A Expense | $73.7M | $69.2M | $70.1M | $67.1M | $99.3M | $108.5M | $106.1M | $97.1M |
| Operating Income | $-3.6M | $-46.9M | $-56.0M | $-92.0M | $-257.8M | $-297.6M | $-251.9M | $-238.8M |
| Operating Margin | -3.4% | -72.9% | -97.6% | -179.1% | -466.1% | -414.2% | -343.1% | -395.5% |
| Interest Expense | — | — | $2.4M | $6.4M | $8.5M | $8.5M | $31.9M | $10.5M |
| Pretax Income | $129.2M | $-44.6M | $-49.3M | $-92.8M | $-265.2M | $-303.3M | $-241.7M | $-226.1M |
| Income Tax Expense | $23.4M | $11.8M | $5.9M | $9.0K | $-151.0K | $-8.5M | $-5.2M | $-10.6M |
| Net Income | $105.9M | $-56.4M | $-55.2M | $872.1M | $-199.4M | $-278.0M | $-236.5M | $-215.5M |
| Net Margin | 98.5% | -87.6% | -96.1% | 1,698.5% | -360.6% | -386.9% | -322.1% | -357.0% |
| EPS (Basic) | $2.10 | $-1.15 | $-1.00 | $11.85 | $-2.87 | $-4.46 | $-4.25 | $-3.99 |
| EPS (Diluted) | $2.06 | $-1.15 | $-1.00 | $11.85 | $-2.87 | $-4.46 | $-4.25 | $-3.99 |
| Shares Outstanding (Basic) | 50.3M | 48.8M | 55.3M | 73.6M | 69.5M | 62.3M | 55.6M | 55.1M |
| Shares Outstanding (Diluted) | 51.5M | 48.8M | 55.3M | 73.6M | 69.5M | 62.3M | 55.6M | 54.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |